metallic taste in mouth; for COVID-19 treatment; previously received COVID 19 vaccine AD26; This spontaneous case was reported by a consumer and describes the occurrence of DYSGEUSIA (metallic taste in mouth), COVID-19 (for COVID-19 treatment) and INTERCHANGE OF VACCINE PRODUCTS (previously received COVID 19 vaccine AD26) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033F21A) for Prophylactic vaccination.    Co-suspect product included non-company product COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) for Prophylactic vaccination.    Concurrent medical conditions included Drug allergy and Cough (Using cough suppressant Robitussin). Concomitant products included ETHINYLESTRADIOL, NORGESTIMATE (TRI-LO-SPRINTEC) for Birth control, DEXTROMETHORPHAN HYDROBROMIDE, ETHANOL, GUAIFENESIN (ROBITUSSIN [DEXTROMETHORPHAN HYDROBROMIDE;ETHANOL;GUAIFENESIN]) for Cough suppression.   On 11-Mar-2021, the patient received first dose of COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) (unknown route) 1 dosage form. On 05-Nov-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Nov-2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (previously received COVID 19 vaccine AD26). On 25-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced DYSGEUSIA (metallic taste in mouth). In 2022, the patient experienced COVID-19 (for COVID-19 treatment). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) on 25-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, DYSGEUSIA (metallic taste in mouth), COVID-19 (for COVID-19 treatment) and INTERCHANGE OF VACCINE PRODUCTS (previously received COVID 19 vaccine AD26) outcome was unknown.            It was reported that event Suspected COVID-19 received treatment. Patient was on contraceptive therapy using Tri-Lo-Sprintec currently. It was reported that Patient was taking other medications/Products within 2 weeks of initiating covid-19 treatment. It was reported that this case was associated with product quality compliant number: 90000235217 Sender/company comment: Covid-19 vaccine ad26.cov2. s-suspected clinical vaccination failure. The events has an unknown/unclear temporal relationship, was unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the events than the drug. Specifically special situations. Therefore this events is considered as not related.  Company Comment: This is a spontaneous case of Interchange of vaccine products concerning a patient of unspecified age and sex, previously vaccinated with a dose of COVID-19 AD26 (dose 1 in COVID-19 vaccine series), with a medical history of suspected COVID-19 following COVID-19 AD26 vaccine, who experienced the unexpected non-serious events of COVID-19 (AESI) and Dysgeusia (metallic taste in mouth). Event COVID-19 occurred unspecified number of days after receiving a dose of mRNA-1273 Vaccine, dose 2 in vaccine series while event Dysgeusia occurred approximately 6 ½ months after vaccination, same day that Paxlovid was started for COVID-19 treatment. Event dysgeusia can also be related to COVID-19. There is no available information regarding clinical course. Paxlovid treatment remains a confounder for event dysgeusia as this can be an adverse effect of the said drug. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case of Interchange of vaccine products concerning a patient of unspecified age and sex, previously vaccinated with a dose of COVID-19 AD26 (dose 1 in COVID-19 vaccine series), with a medical history of suspected COVID-19 following COVID-19 AD26 vaccine, who experienced the unexpected non-serious events of COVID-19 (AESI) and Dysgeusia (metallic taste in mouth). Event COVID-19 occurred unspecified number of days after receiving a dose of mRNA-1273 Vaccine, dose 2 in vaccine series while event Dysgeusia occurred approximately 6 ½ months after vaccination, same day that Paxlovid was started for COVID-19 treatment. Event dysgeusia can also be related to COVID-19. There is no available information regarding clinical course. Paxlovid treatment remains a confounder for event dysgeusia as this can be an adverse effect of the said drug. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.